Dr. Baosheng Chen joined the Department of Medicine, Division of Gastroenterology on July 1, 2017.
He has extensive research experience and expertise in laboratory and translational molecular oncology as well as developmental biology. His PhD training in Cell Biology and Oncology was focused on identifying tumor suppressor genes and mechanistically studying their biological functions in the carcinogenesis of esophageal cancer. He completed post-doctoral training in Developmental Biology and also worked in the field of trophoblast physiology. He has a major interest in translating basic science discoveries to human disease. His current research interests focus on exploration of novel therapeutic methods for colorectal cancer, including combining immunotherapeutic targeting together with traditional chemoradiation. A major focus of his current investigations are on an immune regulatory enzyme, Indoleamine 2,3 Dioxygenase 1 (IDO1), which is an important regulator of the inflammatory response and as modifier of colitis associated cancer progression. Using IDO1 specific inhibitors in combination with immune check point inhibitors, as well as radiation therapy on animal models, he and his colleagues are developing therapeutic strategies in combating colorectal cancers and other malignancies, such as gliomas.